A Study of MEHD7945A in Combination With Cisplatin and 5-FU or Paclitaxel and Carboplatin on Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

This open-label, multicenter study will evaluate the safety, pharmacokinetics and antitumor activity of MEHD7945A in patients with recurrent/metastatic squamous cell carcinoma of the head and neck. Patients will receive MEHD7945A intravenously every 3 weeks in combination with a maximum of 6 cycles of either cisplatin plus 5-FU or carboplatin plus paclitaxel. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.